Loading
Life sciences · Journal article
Babcock University Medical Journal · October 31, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: Polycystic ovary syndrome (PCOS) is a common endocrine disorder with heterogeneous metabolic and reproductive features. Novel circulating biomarkers may improve phenotypic characterization. This study aimed to compare serum kallistatin and vasorin levels between women with PCOS and healthy controls and to examine their associations with body mass index (BMI), insulin resistance (IR), and reproductive hormones. Methods: This case‑control study enrolled 120 women aged 18–45 years from Southern Iraq: 60 diagnosed with PCOS by Rotterdam criteria and 60 healthy controls. Serum kallistatin and vasorin were measured by enzyme‑linked immunosorbent assay. Metabolic and hormonal parameters were assessed using automated biochemical and electrochemiluminescence immunoassays. Statistical analyses included independent t‑tests, Mann–Whitney U tests, Spearman correlations, and receiver operating characteristic (ROC) curve analysis. Results: Women with PCOS had significantly higher serum kallistatin (3.37 ± 0.85 vs. 2.13 ± 0.96 ng/mL, p < 0.001) and lower serum vasorin (62.72 ± 9.86 vs. 94.92 ± 10.31 pg/mL, p < 0.001) than controls. Kallistatin was significantly higher in those with elevated BMI (3.55 ± 0.82 vs. 2.77 ± 0.67 ng/mL, p = 0.003) and with high IR (3.62 ± 0.85 vs. 2.72 ± 0.40 ng/mL, p < 0.001). Vasorin showed no significant association with BMI or IR but was lower in women with high testosterone (60.27 ± 9.82 vs. 63.53 ± 9.84 pg/mL, p = 0.006). ROC analysis yielded areas under the curve of 0.829 for kallistatin and 0.988 for vasorin. Conclusions: Serum kallistatin and vasorin are altered in PCOS and show distinct association patterns: kallistatin with metabolic features (obesity, insulin resistance) and vasorin with androgen status. These findings support further investigation of both molecules as adjunctive biomarkers, pending validation in independent cohorts.